Eton Pharmaceuticals acquires U.S. commercialization rights to IMPAVIDO for leishmaniasis treatment

Eton Pharmaceuticals entered into a supply and distribution agreement to gain exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from Knight Therapeutics, effective September 26, 2026. The acquisition of this FDA-approved orphan drug expands Eton's rare disease portfolio and represents another 2026 product launch for the company.